Outset Medical, Inc. (OM) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents mixed signals. Financial performance shows a revenue decline, but improved margins and reduced net loss. The next-gen Tablo launch and increased service revenue provide optimism, but cash usage and competitive pressures are concerns. The Q&A reveals confidence in future guidance, yet lacks specifics on capital order delays. Thus, the sentiment is neutral, as positives and negatives balance out.
Key Financial Performance
Revenue $27.9 million, a 6% decrease from $29.8 million in the first quarter of 2025, largely due to some lumpiness in the timing of capital orders.
Product Revenue $18.6 million, down 13% year-over-year. This was anticipated due to the timing of capital orders, with about $1 million in capital deals shifted from the first quarter to later in the year.
Service and Other Revenue $9.3 million, a 10% increase from $8.5 million in the prior year period, reflecting strong execution.
Recurring Revenue $22.5 million, roughly flat sequentially and with the first quarter of 2025, as anticipated.
Non-GAAP Gross Margin 43.8%, expanded 620 basis points from last year, driven by sales mix and margin expansion programs.
Product Gross Margin 52.4%, increased 400 basis points from 48.4% in the first quarter of 2025, driven by sales mix.
Service and Other Gross Margin 26.7%, increased more than 1,600 basis points compared to 10.3% in the first quarter of 2025, reflecting strong execution.
Non-GAAP Operating Expenses $25.6 million, increased nearly 4% compared to $24.6 million in the first quarter of 2025, driven by investments in systems and people.
Non-GAAP Operating Loss $13.4 million, even with the prior year period.
Non-GAAP Net Loss $15.4 million, improved 32% compared to $22.8 million in the first quarter of 2025, reflecting progress towards profitability.
Cash Position $161 million in cash, cash equivalents, short-term investments, and restricted cash. Approximately $12 million was used during the quarter, less than previously forecasted due to expense discipline and working capital management.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Next-generation Tablo launch: The company is preparing for the launch of the next-generation Tablo dialysis system later this quarter. This system is the first dialysis system cleared under the FDA's 2025 cybersecurity requirements and includes hardware and software enhancements to improve performance and reliability. It offers significant cybersecurity benefits, which have been well-received in early customer discussions.
Expansion in acute and post-acute care providers: The company is expanding its presence with acute and post-acute care providers. Successful go-live implementations occurred at more than 30 facilities involving nearly 200 consoles in the second quarter.
Gross margin expansion: Non-GAAP gross margin expanded 620 basis points year-over-year to 43.8% in Q1 2026, driven by sales mix and operational efficiencies. Product gross margin reached 52.4%, and service and other gross margin grew significantly to 26.7%.
Cash management: The company ended Q1 2026 with $161 million in cash and used $12 million during the quarter, which was less than forecasted due to expense discipline and working capital management. The company anticipates using less than $40 million for the remainder of the year, a 15% improvement from prior expectations.
Focus on profitability: The company is focused on achieving profitability through margin expansion, disciplined spending, and operational efficiencies. Non-GAAP net loss improved by 32% year-over-year in Q1 2026.
Leadership addition: Derick Elliott joined as EVP of Commercial, bringing extensive experience in sales leadership and pipeline management. His priorities include preparing for the next-generation Tablo launch and advancing customer engagement.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Capital Sales Variability: Variability in the timing of capital orders has impacted quarterly revenue, creating unpredictability in financial performance.
Cybersecurity Risks: The company highlighted the importance of meeting FDA's 2025 cybersecurity requirements to reduce risks of system compromise, unauthorized access, and patient safety concerns.
Operational Transition Risks: The transition to the next-generation Tablo system involves operational challenges, including ensuring smooth implementation and customer adoption.
Cash Management: Although cash usage was lower than forecasted, the company still anticipates using a significant amount of cash for the remainder of the year, which could strain financial resources.
Market Competition: The company faces competitive pressures in the dialysis market, requiring continuous innovation and differentiation to maintain its market position.
Supply Chain and Manufacturing: The company is working to streamline supply chain and manufacturing operations, which could pose risks if not effectively managed.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance for 2026: The company expects revenue to be in the range of $125 million to $130 million, representing a 5% to 9% increase over 2025. The majority of growth is anticipated in the third and fourth quarters.
Gross Margin Projections: Non-GAAP gross margin is expected to be in the low to mid-40% range for the full year, influenced by a mix of console shipments and consumables.
Next-Generation Tablo Launch: The next-generation Tablo dialysis system, which meets FDA's 2025 cybersecurity requirements, will begin a limited release later in the second quarter, extend into the third quarter, and ramp to a full launch. Early customer feedback has been positive, particularly regarding cybersecurity benefits.
Capital Sales and Pipeline: Several large new deals are in late stages of closing, and there is an emerging refresh opportunity with existing customers intending to buy replacement units in future quarters and years.
Cash Usage for 2026: The company anticipates using less than $40 million in cash for the remainder of the year, approximately 15% better than previously expected.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What caused the variability and lumpiness in capital orders, and when are the delayed sales expected to occur?
A:The variability and lumpiness in capital orders are due to the less predictable nature of the capital sales cycle compared to the stability of Tablo utilization. The pipeline for 2026 and beyond remains robust, with several large deals in late stages expected to close in 2026. The delayed sales are anticipated to occur in Q2 through Q4, supported by the next-generation Tablo launch and a new commercial leader.
Q:How should we think about the quarterly phasing and flow of revenue for the year?
A:Q2 is expected to see a modest step-up in revenue, with larger growth percentages in Q3 and Q4. The revenue growth will be sequential across quarters, not concentrated solely in Q4. Approximately 70% of revenue comes from consumables, services, and other recurring sources, which are expected to grow steadily by 5% to 9%.
Q:What drives confidence in the guidance despite delayed orders in Q1?
A:Confidence is driven by the staging of deals in the pipeline, historical data on the probability of closing deals, and the expected demand for the next-generation Tablo system, which meets stringent FDA cybersecurity requirements. These factors, along with early positive feedback from sales conversations, support the guidance.
Q:Can the next-generation Tablo system accelerate trade-in timelines for older units?
A:Yes, the next-generation Tablo system has the potential to accelerate trade-in timelines for older units.
Q:What is the functionality of bidirectional integration of Tablo into the EMR, and how does it impact revenue?
A:Currently, Tablo offers one-way data transfer to EMRs like Epic and Cerner, which is unique. A future bidirectional integration would allow prescription data to be transmitted from the EMR to Tablo, adding value for customers. This feature could create incremental revenue opportunities, further strengthening the recurring revenue foundation, which is about 70% of total revenue.
Q:Review of Unclear Management Responses
A:Management avoided directly addressing why the capital order sales cycle is less predictable and did not provide specific details on the exact timing or reasons for the delays in Q1 sales. Additionally, while they expressed confidence in the guidance, the explanation relied heavily on generalities like historical data and pipeline staging without concrete evidence or examples.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Capital sale
Commercial Gaeta
EVP Commercial
FDA cybersecurity
Principal
access
addition
afternoon Outset
capital order
capital sale
control
dialysis system
enhancement
expertise
fit
generation Tablo
hospital health
implementation
launch generation
leader Elliott
lumpiness
margin end
methodology
mix
people
priority
procedure place
provider
quarter
sale plan
service margin
software
system FDA
team
timing capital
transition
value proposition
OM Transcript
Outset Medical, Inc. (OM) Q1 2026 Earnings Call Transcript
Unknown5-9
The earnings call presents mixed signals. Financial performance shows a revenue decline, but improved margins and reduced net loss. The next-gen Tablo launch and increased service revenue provide optimism, but cash usage and competitive pressures are concerns. The Q&A reveals confidence in future guidance, yet lacks specifics on capital order delays. Thus, the sentiment is neutral, as positives and negatives balance out.
Outset Medical, Inc. (OM) Q4 2025 Earnings Call Transcript
Unknown2-11
While the company has shown improvements in operating expenses and net loss, revenue guidance has been lowered. The Q&A revealed positive sentiment towards the next-gen Tablo's potential impact but lacked specifics on ASP lift and gross margin timelines, which may cause uncertainty. The mixed signals from strong financial metrics but weak guidance, coupled with optimistic future prospects, suggest a neutral short-term stock price movement.
Outset Medical, Inc. (OM) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-14
Outset Medical, Inc. (OM) Q3 2025 Earnings Call Transcript
Unknown11-10
The earnings call presents a mixed picture. Financial performance shows improvement with increased gross margins and reduced losses, but challenges remain with sales leadership changes and guidance reduction. The Q&A reveals uncertainties in deal timing and sales leadership, though no order cancellations occurred. Raised revenue guidance for 2025 is positive, yet the lack of 2026 guidance and management's vague responses add uncertainty. Overall, the sentiment is neutral due to balancing positive financial trends with leadership and guidance concerns.
OM Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
